- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07710183
Pumpkin Seed Oil as a Nutraceutical for Hemodialysis Patients
Potential Role of Pumpkin Seed Oil as a Nutraceutical on the Clinical and Biochemical Outcomes in Hemodialysis Patients
연구 개요
상태
상세 설명
Chronic systemic inflammation is a cornerstone of hemodialysis pathophysiology, driven by uremic toxin retention, oxidative stress, endotoxemia, and repeated exposure to bioincompatible dialysis membranes, which activate NF-κB and STAT signaling and sustain elevated IL-6 and CRP. These biomarkers are independent predictors of cardiovascular and all-cause mortality, and contribute to the malnutrition-inflammation complex syndrome (MICS) that affects a substantial proportion of dialysis patients. sVCAM-1 acts as a mechanistic bridge between the uremic milieu and accelerated atherosclerosis, mediating monocyte adhesion to the arterial intima and serving as an independent predictor of cardiovascular mortality in this population.
No pharmacological agent is currently routinely or universally prescribed to specifically target inflammation in hemodialysis patients; existing options (e.g., anti-IL-6 agents, statins, pentoxifylline, nutraceuticals such as curcumin, omega-3 fatty acids, and vitamin E) show variable biomarker reductions but have not been widely incorporated into standard practice. Pumpkin seed oil has shown anti-inflammatory and antioxidant effects in animal and in vitro studies, including suppression of IL-1β, IL-6, TNF-α, and COX-2, with effects in some models comparable to NSAIDs. Vitamin E, a major constituent of pumpkin seed oil, has separately been shown to reduce circulating sVCAM-1 in hemodialysis patients via suppression of oxidative stress. However, to the investigators' knowledge, no prior human study has directly examined the impact of pumpkin seed oil on IL-6 and CRP in hemodialysis patients, and no study has investigated its effect on sVCAM-1 specifically in this population.
This study addresses that gap by evaluating the effect of 1000 mg/day oral pumpkin seed oil for 3 months, in addition to usual hemodialysis care, on inflammatory (IL-6, hsCRP, sVCAM-1), oxidative stress (MDA, SOD), and lipid biomarkers, compared with a usual-care control group, in patients with ESRD on maintenance hemodialysis at the Hemodialysis Center, Al-Karama Teaching Hospital, Iraq.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: mohammed mahmood M mohammed, professor
- 전화번호: +964 07816871131
- 이메일: pharm.drmhdclinical@uomustansiriyah.edu.iq
연구 장소
-
-
Karkh
-
Baghdad, Karkh, 이라크, 10064
- 모병
- Al-Karama Teaching Hospital, Hemodialysis Center
-
연락하다:
- Rana Bahaa Mohammed, MSc
- 전화번호: 00964 7705846087
- 이메일: rana_clinicalphd@uomustansiriyah.edu.iq
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- End-stage renal disease (ESRD) on hemodialysis for more than 6 months, on a constant dialysis program.
- Hemodynamically stable (no recent hospitalization for infections, cardiovascular events, or major surgery within the past 3 months).
- No active acute infections.
- Serum albumin ≥ 3.0 g/dL.
Exclusion Criteria:
- Regular intake of dietary supplements (e.g., omega-3, antioxidants) for at least one month prior to enrollment.
- Autoimmune disease, liver disease, cancer, or acquired immunodeficiency syndrome (AIDS).
- Known sensitivity/allergy to pumpkin seed oil.
- Current use of lipid-lowering agents.
- Diabetes mellitus.
- Current use of anticoagulants (warfarin, direct oral anticoagulants).
- Current use of immunosuppressants, corticosteroids, or anti-inflammatory drugs.
- Pregnant or breastfeeding women.
- Residual kidney function (urine output > 200 mL/day).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Pumpkin Seed Oil + Usual Care
Participants receive pumpkin seed oil 1000 mg orally once daily for 3 consecutive months, in addition to their standard hemodialysis usual care.
|
Pumpkin seed oil, 1000 mg, oral capsule/tablet, once daily (taken on dialysis days after the dialysis session), for 3 months, added to the standard hemodialysis care protocol.
Standard hemodialysis care per center protocol, with no additional study supplement.
|
|
활성 비교기: Usual Care (Control)
Participants =continue routine hemodialysis usual care only, without pumpkin seed oil or placebo.
|
Standard hemodialysis care per center protocol, with no additional study supplement.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Serum Interleukin-6 (IL-6) level
기간: Baseline and 3 months
|
Change in serum Interleukin-6 (IL-6) level
|
Baseline and 3 months
|
|
Serum high-sensitivity C-reactive protein (hsCRP) level
기간: Baseline and 3 months
|
Change in high-sensitivity C-reactive protein (hsCRP) level
|
Baseline and 3 months
|
|
Serum soluble vascular cell adhesion molecule-1 (sVCAM-1) level
기간: Baseline and 3 months
|
Change in soluble vascular cell adhesion molecule-1 (sVCAM-1) level
|
Baseline and 3 months
|
|
Serum lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides) levels
기간: Baseline and 3 months
|
Change in lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides) level
|
Baseline and 3 months
|
|
Serum malondialdehyde (MDA) level
기간: Baseline and 3 months
|
Change in malondialdehyde (MDA) level
|
Baseline and 3 months
|
|
Serum superoxide dismutase (SOD) activity
기간: Baseline and 3 months
|
Change in superoxide dismutase (SOD) activity
|
Baseline and 3 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SOP117
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
염증에 대한 임상 시험
-
Actavis Inc.Watson Laboratories, Inc.완전한세균성 질염 | 평가 및 기록할 징후 및 증상은 다음과 같습니다. | 질 분비물의 색, 냄새 및 일관성 | 외음부 가려움증 및 자극(주관적) 없음, 경미함, 보통 또는 심함 | Vulvovaginal Inflammation (Objective) 부재, 경증, 중등도 또는 중증미국, 도미니카 공화국, 푸에르토 리코
Pumpkin Seed Oil 1000 mg에 대한 임상 시험
-
Zhejiang Kanglaite Pharmaceutical Co.LtdLinkDoc Technology (Beijing) Co. Ltd.; NanJing PLA 81 Hospital알려지지 않은
-
Mylan Pharmaceuticals Inc완전한
-
Mylan Pharmaceuticals Inc완전한
-
Centre Hospitalier Universitaire, AmiensMerck Serono International SA완전한
-
Boryung Pharmaceutical Co., Ltd모병
-
Boryung Pharmaceutical Co., Ltd모병